Recent Postings to

Worst Pills, Best Pills Newsletter Articles

  View the entire December 2017 issue in PDF format

  • The Dangerous Diabetes Drug Pramlintide: Do Not Use
    (December 2017)
    In this article, we explain why the serious adverse effects of the injected diabetes drug pramlintide far outweigh the drug’s limited benefits.
  • At the Behest of the Opioid Drug Industry, Congress Undermined the DEA
    (December 2017)
    Worst Pills, Best Pills News Editor Dr. Michael Carome discusses how the opioid drug industry successfully lobbied Congress to pass a dangerous bill that effectively stripped the Drug Enforcement Agency of one of its strongest enforcement tools for fighting the illegal diversion of opioid drugs.
  • Drugs That Cause Weight Gain
    (December 2017)
    Weight gain is an adverse event associated with many widely used medications and may lead to significant overweight and obesity, especially in susceptible individuals. Find out which drugs have this adverse effect.
  • Drug for Treating Nighttime Urination Too Dangerous
    (December 2017)
    Nighttime urination is a common symptom that becomes more common with increasing age. Learn why the only drug approved for treating this symptom offers only meager benefits along with unacceptable risks.
  • Rifaximin (XIFAXAN): Another Poor Choice for Treating Irritable Bowel Syndrome
    (December 2017)
    Rifaximin was approved by the FDA in May 2015 for treating irritable bowel syndrome with diarrhea as the predominant symptom in adults. Find out about the drug’s serious adverse effects that outweigh its limited benefits.

  View the entire November 2017 issue in PDF format

  • Do Not Use the New Blood Thinner Edoxaban (SAVAYSA)
    (November 2017)
    Learn why edoxaban, one of the new blood thinners approved by the FDA, is not the best option for preventing dangerous blood clots in patients with atrial fibrillation.
  • FDA Cracks Down on Illegal Stem Cell Treatments
    (November 2017)
    Over the past decade, the number of clinics in the U.S. that peddle unproven stem cell "treatments" directly to consumers exploded from a handful in 2010 to as many as 570 in 2016. Find out what the FDA is finally doing to clamp down on the marketing of illegal stem cell treatments.
  • Corticosteroid Injections Not Beneficial for Knee Osteoarthritis
    (November 2017)
    The injection of corticosteroids into the knee joints of patients with osteoarthritis of the knee is a widespread practice. Find out the results of new research funded by the National Institutes of Health showing that such injections actually may accelerate joint damage.
  • Subclinical Hypothyroidism: When to Treat
    (November 2017)
    In this article, we describe a common condition known as subclinical hypothyroidism and discuss which patients with this condition should be treated with thyroid hormone replacement.
  • News Brief for November 2017
    (November 2017)
    In this month’s news brief, we report the FDA’s reckless decision to deny Public Citizen’s petition to ban a dangerous anti-fungal drug.
  • Pregabalin (LYRICA): Neither Effective nor Safe for Treating Sciatica Leg Pain
    (November 2017)
    Doctors often prescribe pregabalin for a neuropathic pain condition known as sciatica, a use that is not approved by FDA. Find out why pregabalin is a bad choice for treating sciatica.

  View the entire October 2017 issue in PDF format

  • U.S. Senate Passes 'False-Hope' Act
    (October 2017)
    In August, the U.S. Senate unanimously passed the so-called Right to Try Act. Worst Pills, Best Pills News Editor Dr. Michael Carome explains how this deceptively named bill would put countless patients at risk by undermining important FDA safety rules related to the use of unapproved, experimental medications.
  • News Brief for October 2017
    (October 2017)
    In this month’s news brief, we report on the FDA’s recent decision to partially grant a petition from Public Citizen to require the addition of a warning about a dangerous drug-drug interaction to product labeling of repaglinide-containing diabetes medications.
  • Tofacitinib (XELJANZ): The Wrong Choice for Rheumatoid Arthritis
    (October 2017)
    Tofacitinib is one of the newer medications approved by the FDA for treatment of rheumatoid arthritis. Learn why we have designated this drug as Do Not Use.
  • Diabetes Drug Canagliflozin Doubles Risk of Amputations, FDA Warns
    (October 2017)
    Canagliflozin is one of three medications in the newest diabetes drug class. In this article, we discuss why the FDA recently required that a black-box warning about the risk of amputations be added to the product labeling of canagliflozin.
  • Vitamin E Does Not Prevent Declines in Memory and Cognitive Function
    (October 2017)
    Dietary supplement makers often tout vitamin E products for a variety of purported health benefits, including the promotion of brain health. Find out why vitamin E supplements are unlikely to prevent cognitive decline and may cause serious harm if taken in doses exceeding the recommended dietary allowance.
  • Injected Naltrexone for Opioid Addiction
    (October 2017)
    Hear how drugmaker Alkermes has engaged in a novel but troubling marketing campaign to increase sales of its once-monthly injected version of naltrexone (VIVITROL) for treatment of opioid addiction.
Copyright © 2017 Pill. All rights reserved.